On August 21, 2019 Genmab A/S (Nasdaq: GMAB) reported that preliminary data from the Phase I/II trial of enapotamab vedotin in advanced non-small cell lung cancer (NSCLC) has been accepted for oral presentation at the International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer (IASLC 2019 WCLC) taking place from September 7-10, 2019 in Barcelona, Spain (Press release, Genmab, AUG 21, 2019, View Source [SID1234538927]). Meeting abstracts are currently accessible form the IASLC 2019 WCLC website, View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored that early data from enapotamab vedotin was chosen for oral presentation at the IASLC 2019 WCLC. The selection of this data for presentation also supports our belief in the potential of this first-in-class compound for patients with advanced non-small cell lung cancer progressing on chemotherapy and a checkpoint inhibitor; we look forward to more advanced and complete data becoming available in the future" said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Enapotamab vedotin abstract to be presented:
First-in-human Phase 1/2 trial of anti-AXL antibody–drug conjugate enapotamab vedotin in advanced NSCLC – Oral presentation, Sunday, September 8, 2019, 11:15 AM – 11:25 AM CEST. Full abstract available here.